...
首页> 外文期刊>Neuropharmacology >Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax.
【24h】

Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax.

机译:慢性锂对小鼠预防MPTP(N-甲基-4-苯基-1,2,3,6-四氢吡啶)多巴胺能神经毒性:Bcl-2和Bax的参与。

获取原文
获取原文并翻译 | 示例
           

摘要

Lithium has been reported to exert neuroprotective activity in several neuronal cell cultures and in vivo models against glutamate toxicity. Since this action was reported to be associated with alterations in the antiapoptotic Bcl-2 family proteins, the effect of chronic lithium diet on the ability of the parkinsonism neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to deplete striatal dopamine in mice was determined. Mice were fed for with a diet containing 1.1, 2.2, 3.3, and 4.4 g/kg lithium chloride (LiCl) for 4 weeks, during which time serum levels of lithium were monitored. The 3.3 g/kg lithium diet gave serum level value very similar to what is observed in lithium therapy in man and the 4.4 g/kg well above this. At the end of this period the mice received 24 mg/kg MPTP i.p. once daily for 3 days. A direct relation was established with the increase in serum lithium and its ability to prevent MPTP induced depletion of striatal dopamine (DA) and its metabolites DPOAC and HVA. With thediet containing the highest lithium concentration there was an almost complete prevention of striatal dopamine depletion and the reduction in tyrosine hydroxylase activity and protein and it prevented the increase in dopamine turnover (DOPAC + HVA/DA) normally observed in MPTP treatment. Lithium did not interfere with the metabolism of MPTP, or with its brain uptake, since, the level of its monoamine oxidase (MAO) B derived metabolite, MPP+, in the striata of lithium and non-lithium treated mice were almost identical. Striatal Bcl-2 was significantly decreased, while Bax was increased in MPTP treated mice. Lithium treatment not only increased striatal Bcl-2 in control mice, but also prevented its reduction as induced by MPTP, and an opposing effect was seen with Bax. The neuroprotective action of lithium in this model of Parkinson's disease has been attributed to its antiapoptotic activity which among other factors includes induction of Bcl-2 and reduction of Bax.
机译:据报道,锂在几种神经元细胞培养物中和针对谷氨酸毒性的体内模型中发挥神经保护活性。由于据报道该作用与抗凋亡Bcl-2家族蛋白的改变有关,因此慢性锂饮食对帕金森氏症神经毒素N-甲基-4-苯基-1,2,3,6-四氢吡啶的能力的影响(MPTP)消耗小鼠纹状体多巴胺。用含1.1、2.2、3.3和4.4g / kg氯化锂(LiCl)的饮食喂养小鼠4周,在此期间监测血清锂水平。 3.3 g / kg锂饮食的血清水平非常类似于男性锂疗法中观察到的水平,而4.4 g / kg远远高于此水平。在这一时期结束时,小鼠腹膜内接受24mg / kg MPTP。每天一次,持续3天。与血清锂的增加及其预防MPTP诱导纹状体多巴胺(DA)及其代谢产物DPOAC和HVA消耗的能力建立了直接关系。在饮食中锂含量最高的情况下,几乎完全可以预防纹状体多巴胺的消耗以及酪氨酸羟化酶活性和蛋白质的减少,并且可以防止MPTP处理中通常观察到的多巴胺周转率增加(DOPAC + HVA / DA)。锂不会干扰MPTP的代谢或大脑的摄取,因为锂和未经锂处理的小鼠纹状体中单胺氧化酶(MAO)B衍生的代谢产物MPP +的水平几乎相同。在MPTP处理的小鼠中,纹状体Bcl-2显着降低,而Bax升高。锂处理不仅增加了对照小鼠的纹状体Bcl-2含量,而且还阻止了MPTP诱导的纹状体Bcl-2含量降低,并且Bax产生了相反的作用。锂在帕金森氏病模型中的神经保护作用归因于其抗凋亡活性,其中除其他因素外,还包括诱导Bcl-2和降低Bax。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号